NASDAQ · DYN
Dyne Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for DYN: Nov 4, 2026
Dyne Therapeutics, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 8 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.88. The reported EPS for the same quarter last year was $-0.76.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.88 | $-0.73 | $-1.09 | 8 |
| Dec 2026 | $-0.85 | $-0.36 | $-1.11 | 8 |
| Mar 2027 | $-0.89 | $-0.75 | $-0.97 | 3 |
| Jun 2027 | $-0.85 | $-0.78 | $-0.98 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · Barchart- BNK Invest · Oct 12, 4:55 PM EDTOversold Conditions For Dyne Therapeutics (DYN)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- BNK Invest · Oct 1, 3:25 PM EDTNoteworthy Thursday Option Activity: WULF, DYN, ASTSLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in TeraWulf Inc. (Symbol: WULF), where a total volume of 184,174 contracts has been traded thus far today, a contract volume which is representative of approximatel
- RTTNews · Sep 30, 1:41 AM EDTDyne Reports One-Year Z-Basivarsen Data Showing Functional Improvements In DM1(RTTNews) – Dyne Therapeutics (DYNE) announced on Tuesday additional one-year clinical data from the Phase 1/2 ACHIEVE trial of investigational Z-basivarsen showing sustained functional improvements across multiple measures in patients with myotonic dystrophy type 1.
- RTTNews · Sep 29, 11:12 PM EDTDyne's DYNE-101 Shows One-Year Functional Improvement In DM1 Study(RTTNews) – Tuesday, Dyne Therapeutics (DYN) reported additional one-year data from the Phase 1/2 ACHIEVE trial showing that zeleciment basivarsen (DYNE-101) improved multiple functional measures in patients with myotonic dystrophy type 1 (DM1).
- Barchart · Sep 10, 2:46 PM EDTStocks Fall as Crude Prices Soar and Bond Yields ClimbThe S&P 500 Index ($SPX ) (SPY ) closed down -0.48% on Wednesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.77%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.29%. E-mini S&P futures (ESU26 ) fell -0.46%, and September E-mini Nasdaq futures (NQU26…
- Barchart · Sep 9, 6:28 PM EDTStocks Pressured as Inflation Fears Boost Bond YieldsThe S&P 500 Index ($SPX ) (SPY ) is down -0.25% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.69%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.12%. E-mini S&P futures (ESU26 ) are down -0.92%, and September E-mini Nasdaq futures (NQU26…
- Barchart · Sep 9, 6:01 PM EDTStocks and Bonds Fall as Crude Oil SurgesThe S&P 500 Index ($SPX ) (SPY ) is down -0.25% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.69%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.12%. E-mini S&P futures (ESU26 ) are down -0.92%, and September E-mini Nasdaq futures (NQU26…
- RTTNews · Sep 8, 8:15 AM EDTDyne Therapeutics Shares Fall 29% As DM1 Rival Fails Phase 3; One-Year Data Ahead(RTTNews) – Dyne Therapeutics Inc. (DYN) shares are down 29.45% after Novartis reported that its Phase 3 HARBOR study of del-desiran in myotonic dystrophy type 1 (DM1) failed to meet its primary endpoint, weighing on shares of Dyne, which is developing z-basivarsen for the same d
- RTTNews · Aug 12, 3:45 AM EDTBiotech Stocks At 52-Week Highs – ALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH(RTTNews) – The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports.
- RTTNews · Jul 30, 6:36 AM EDTDyne Q2 Loss Widens As Phase 3 For DMD Therapy Progresses(RTTNews) – Dyne Therapeutics, Inc. (DYN), reported a wider net loss for the second quarter ended June 30, 2026, and provided various clinical highlights.
- RTTNews · Jul 28, 9:47 AM EDTDyne Therapeutics Receives FDA Clearance To Begin Phase 1 Trial Of DYNE-302 In FSHD(RTTNews) – Dyne Therapeutics Inc. (DYN) announced that the U.S. FDA has cleared its IND application for DYNE-302, enabling the company to initiate a Phase 1 clinical trial in facioscapulohumeral muscular dystrophy (FSHD).
- RTTNews · Jul 28, 4:24 AM EDTBiotech Stocks At 52-Week Highs – LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX,(RTTNews) – The following biotech stocks reached a 52-week high on July 27, 2026, driven by key catalysts including prospective clinical trial results, and the launch of new services.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Dyne Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.